These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22369748)

  • 1. The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.
    Provine NM; Cortez V; Chohan V; Overbaugh J
    Virology; 2012 May; 427(1):25-33. PubMed ID: 22369748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.
    Ringe R; Thakar M; Bhattacharya J
    Retrovirology; 2010 Sep; 7():76. PubMed ID: 20860805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
    von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
    J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained.
    Balla-Jhagjhoorsingh SS; Willems B; Heyndrickx L; Heyndrickx L; Vereecken K; Janssens W; Seaman MS; Corti D; Lanzavecchia A; Davis D; Vanham G
    PLoS One; 2011; 6(10):e25488. PubMed ID: 22016769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1.
    Blish CA; Jalalian-Lechak Z; Rainwater S; Nguyen MA; Dogan OC; Overbaugh J
    J Virol; 2009 Aug; 83(15):7783-8. PubMed ID: 19474105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike.
    Wen M; Arora R; Wang H; Liu L; Kimata JT; Zhou P
    Retrovirology; 2010 Oct; 7():79. PubMed ID: 20923574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma.
    Kumar A; Smith CEP; Giorgi EE; Eudailey J; Martinez DR; Yusim K; Douglas AO; Stamper L; McGuire E; LaBranche CC; Montefiori DC; Fouda GG; Gao F; Permar SR
    PLoS Pathog; 2018 Apr; 14(4):e1006944. PubMed ID: 29672607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
    Nakowitsch S; Quendler H; Fekete H; Kunert R; Katinger H; Stiegler G
    AIDS; 2005 Nov; 19(17):1957-66. PubMed ID: 16260901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.
    Deshpande S; Patil S; Kumar R; Shrivastava T; Srikrishnan AK; Murugavel KG; Koff WC; Chakrabarti BK; Bhattacharya J
    Retrovirology; 2016 Jun; 13(1):41. PubMed ID: 27307004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.
    Dieltjens T; Heyndrickx L; Willems B; Gray E; Van Nieuwenhove L; Grupping K; Vanham G; Janssens W
    Retrovirology; 2009 Dec; 6():113. PubMed ID: 20003438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies.
    Wang H; Yuan T; Li T; Li Y; Qian F; Zhu C; Liang S; Hoffmann D; Dittmer U; Sun B; Yang R
    Arch Virol; 2018 Dec; 163(12):3303-3315. PubMed ID: 30196320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.
    Johnson J; Zhai Y; Salimi H; Espy N; Eichelberger N; DeLeon O; O'Malley Y; Courter J; Smith AB; Madani N; Sodroski J; Haim H
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China.
    Xie H; Nie J; Chen Q; Huang W; Wang Y
    Emerg Microbes Infect; 2018 May; 7(1):90. PubMed ID: 29769530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.